Protalix BioTherapeutics Accounts Payable

Protalix BioTherapeutics (PLX) currently reports a accounts payable of $4.3M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Protalix BioTherapeutics's accounts payable history and peer comparisons.

Protalix BioTherapeutics's accounts payable changed from $0 to $4.3M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Protalix BioTherapeutics reported $4.3M in accounts payable as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $4.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Protalix BioTherapeutics, and consider following PLX for alerts when major investors trade the stock.

Protalix BioTherapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $4.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLX with unrelated industries.